How NICE is retooling the way antibiotics are valued

The U.K.'s NICE is creating a new forward-looking way to evaluate how antimicrobials will be valued. The agency's forthcoming adapted value assessment framework will aim to capture the full benefits of these agents, including their ability to stave off drug resistance at a population level, to inform reimbursement negotiations and stimulate investment in the antibiotic space.

The biggest challenge for the health technology assessment (HTA), which will be used as part of a subscription payment model for antibiotics announced by the U.K. early this month in an attempt to reinvigorate investment in the antimicrobial space, will be to go beyond evaluation of benefits to patients treated now and model the benefits to patients in the future...